MedTrace Logo

Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry

NCT05774431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6789

Last updated 2025-03-30

No results posted yet for this study

Summary

The primary objective of this study is to compare patients eligible for ASS and Ticagrelor against those eligible for ASS and Prasugrel. The available information regarding relative and absolute exclusion criteria outlines reasons for disqualification from either drug.

The secondary objectives of the study are to:

* Assess the proportion of patients who received ASS and Ticagrelor in the study cohort.
* Compare the proportion of patients who received ASS and Ticagrelor against the proportion of patients who qualify for DAPT with ASS and Ticagrelor (eligible group).
* Describe the antithrombotic treatment, including antiplatelet monotherapies, and antiplatelet therapies with or without anticoagulation.

The investigators will use these objectives to evaluate the effectiveness and appropriateness of the different antiplatelet therapies in the study population. Participants will not be personally identified in any reports or publications resulting from this study.

Conditions

  • Acute Myocardial Infarction

Interventions

OTHER

There was no intervention necessary.

There was no intervention necessary.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University Hospital Heidelberg

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05774431 on ClinicalTrials.gov